This site is for general information only and is not medical advice, diagnosis, or treatment. Always talk to a qualified clinician before medical decisions. TrialFinder is not affiliated with trial sponsors or healthcare providers.
On August 26, 2026 the FDA approved daraxonrasib (RASONQUE, Revolution Medicines), a RAS GTPase family inhibitor. The labeled use is adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or who are not candidates for multiagent systemic therapy.
This page was first published in July 2026, when the drug was still investigational and some people could try to reach it through expanded access. That is no longer the current path in the United States. The practical next step is to ask whether the approved use matches the diagnosis and the treatments already given.
In plain language, the FDA decision applies when all of this is true:
"Systemic therapy" usually means treatment that travels through the body, such as chemotherapy. "Multiagent" means more than one drug given together. The oncologist is the one who can say whether this description matches the pathology report, the stage, and the treatments already used.
The approval is a US FDA decision. What is available, covered, or imported elsewhere is a separate question.
Pancreatic cancer has very few targeted options. RAS mutations drive the vast majority of cases. Daraxonrasib is a RAS GTPase family inhibitor, so it is a different class of option than standard chemotherapy. That is why the approval is worth raising, even though it does not fit every person.
Efficacy was evaluated in the randomized RASolute 302 trial. Group results from a trial are not a prediction for one person.
The approval applies to the stated population. It is not a cure.
It does not automatically apply to earlier-stage disease, to every pancreatic tumor type, or to care outside the United States. A longer median survival in a trial is a group result. It is not a promise of how long any one person will live, and it does not mean the cancer is gone.
One approved use does not close the research. Ongoing studies continue to test daraxonrasib in earlier lines of treatment and in combinations.
To see recruiting pancreatic cancer studies, use the full TrialFinder pancreatic cancer search. The pancreatic cancer clinical trials guide explains how stage and biomarkers change which listings may fit. A trial is one option to discuss. It is not automatically better than an approved treatment.
A short list is usually enough:
If it helps to plan the appointment, How to Talk to Your Doctor About Clinical Trials walks through how to raise the topic and what to bring.
No. On August 26, 2026 the FDA approved daraxonrasib (brand name RASONQUE, Revolution Medicines) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or who are not candidates for multiagent systemic therapy. Ask the treating oncologist whether that description matches this case.
The labeled use is adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, or adults who are not candidates for multiagent systemic therapy. It does not automatically cover earlier-stage disease or every pancreatic tumor type. Availability outside the United States depends on local regulators and coverage.
Pancreatic cancer has very few targeted options. RAS mutations drive the vast majority of cases. Daraxonrasib is a RAS GTPase family inhibitor, a different class of option than standard chemotherapy. That does not mean it fits every person, or that it replaces a conversation with the oncologist.
No. Approval applies to the stated population. It is not a cure, and trial results are group results, not a promise for one person.
Yes. Ongoing studies continue to test daraxonrasib in earlier lines of treatment and in combinations. The approved use and a trial listing are different questions. Search TrialFinder for recruiting pancreatic cancer trials and take specific listings to the oncologist.
This article was written by a patient advocate based on personal experience, not by a medical professional. It is not medical advice. Consult your doctor before making any medical decisions.